Patient Satisfaction and Safety
SYNVISC has a demonstrated safety profile and high level of patient satisfaction
Based on a large, observational study to assess its tolerability and short-term effectiveness, SYNVISC has a demonstrated safety profile, and over 80% of patients were satisfied, rating it as a “good” or “very good” therapy at 3 weeks after the first injection1
of patients were satisfied with SYNVISC as their therapy at 3 weeks after the first injection1
Most commonly reported device-related AEs with SYNVISC1:
- Pain in the injected knee
- Swelling in the injected knee
- Joint effusion
Potential AEs that may occur in association with intra-articular injection, including SYNVISC2:
- Arthralgia
- Injection-site pain
- Joint stiffness
- Arthritis
- Joint swelling
- Arthropathy
- Joint warmth
- Gait disturbance
References
- Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-1269.
- SYNVISC [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.
